Literature DB >> 21339734

Mitosis as an anti-cancer target.

A Janssen1, R H Medema.   

Abstract

Most of the current drugs used to treat cancer can be classified as anti-proliferative drugs. These drugs perturb the proliferative cycle of tumor cells at diverse stages of the cell cycle. Examples of such drugs are DNA-damaging agents and inhibitors of cyclin-dependent kinases that arrest cell cycle progression at different stages of interphase. Another class of anti-proliferative drugs is the so-called anti-mitotic drugs, which selectively perturb progression through mitosis. Mitosis is the shortest and final stage in the cell cycle and has evolved to accurately divide the duplicated genome over the two daughter cells. This review deals with the different strategies that are currently considered to perturb mitotic progression in the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21339734     DOI: 10.1038/onc.2011.30

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  49 in total

1.  Up-regulation of pro-apoptotic protein Bim and down-regulation of anti-apoptotic protein Mcl-1 cooperatively mediate enhanced tumor cell death induced by the combination of ERK kinase (MEK) inhibitor and microtubule inhibitor.

Authors:  Takumi Kawabata; Susumu Tanimura; Kohei Asai; Ryohei Kawasaki; Yumi Matsumaru; Michiaki Kohno
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

Review 2.  Decision for cell fate: deubiquitinating enzymes in cell cycle checkpoint.

Authors:  Key-Hwan Lim; Myoung-Hyun Song; Kwang-Hyun Baek
Journal:  Cell Mol Life Sci       Date:  2016-01-13       Impact factor: 9.261

Review 3.  Mitosis as an anti-cancer drug target.

Authors:  Anna-Leena Salmela; Marko J Kallio
Journal:  Chromosoma       Date:  2013-06-18       Impact factor: 4.316

4.  GSI promotes vincristine-induced apoptosis by enhancing multi-polar spindle formation.

Authors:  Akannsha Singh; Mariana C Zapata; Yong Sung Choi; Sun-Ok Yoon
Journal:  Cell Cycle       Date:  2013-10-29       Impact factor: 4.534

5.  First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors.

Authors:  Patricia M LoRusso; Priscila H Goncalves; Lindsay Casetta; Judith A Carter; Kevin Litwiler; Dale Roseberry; Selena Rush; Jennifer Schreiber; Heidi M Simmons; Mieke Ptaszynski; Edward A Sausville
Journal:  Invest New Drugs       Date:  2015-02-17       Impact factor: 3.850

Review 6.  Targeting Cdc20 as a novel cancer therapeutic strategy.

Authors:  Lixia Wang; Jinfang Zhang; Lixin Wan; Xiuxia Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Pharmacol Ther       Date:  2015-04-04       Impact factor: 12.310

7.  Taxane-mediated radiosensitization derives from chromosomal missegregation on tripolar mitotic spindles orchestrated by AURKA and TPX2.

Authors:  M Orth; K Unger; U Schoetz; C Belka; K Lauber
Journal:  Oncogene       Date:  2017-09-04       Impact factor: 9.867

8.  Regulation of polo-like kinase 1 by DNA damage and PP2A/B55α.

Authors:  Ling Wang; Qingyuan Guo; Laura A Fisher; Dongxu Liu; Aimin Peng
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

9.  KIBRA regulates aurora kinase activity and is required for precise chromosome alignment during mitosis.

Authors:  Lin Zhang; Jyoti Iyer; Aparajita Chowdhury; Ming Ji; Ling Xiao; Shuping Yang; Yuanhong Chen; Ming-Ying Tsai; Jixin Dong
Journal:  J Biol Chem       Date:  2012-08-17       Impact factor: 5.157

10.  The expression of Nek7, FoxM1, and Plk1 in gallbladder cancer and their relationships to clinicopathologic features and survival.

Authors:  R Wang; Y Song; X Xu; Q Wu; C Liu
Journal:  Clin Transl Oncol       Date:  2013-01-29       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.